Navigation Links
ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference
Date:5/4/2010

he time of diagnosis over the course of a lifetime, layering additional therapies as flare-ups recur or persist in an effort to reduce symptoms. When medications can no longer control symptoms, patients have few options beyond surgery.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors.  Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial. In addition, CCX025, also a CCR9 antagonist, has successfully completed a Phase I clinical program. Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; and CCX168, a C5aR antagonist, in Phase I clinical development. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more information, please refer to

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014   Ventana Medical Systems, ... today announced that its VENTANA System for Primary ... the European Union for routine pathology, including primary ... of VENTANA Virtuoso software coupled with either the ... slide scanner, provides automated digital slide creation, case ...
(Date:8/20/2014)... -- Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, ... FDA (CFDA) approval and has subsequently launched its ... China domestic market.  Under the ... Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen is manufacturing ... China CFDA certified oral solid dose facility in ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: The Market ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle Eastern and ... medical devices. As part of its coverage, this ... concentrates on the EMEA medical device markets and ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5
... at the , 2007 American Society of Clinical ... Patients with AML and in,Refractory , ALL Patients ... Aloxi(R),with , the 5-HT3 Receptor Reported-- , --Results ... with Multimodal Therapy, including Gliadel(R) Described-- , --Survival ...
... June 05, 2007 /PRNewswire-USNewswire/ -- The Barbara,Ann Karmanos ... of medicine and oncology, presented the outcome,of one ... clinical,trials in North America and chaired an education ... the American Society of,Clinical Oncology (ASCO) annual meeting ...
Cached Medicine Technology:MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 10Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed 2Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed 3
(Date:8/20/2014)... both breast cancer relapses and responses to chemotherapy, ... newly found marker could help doctors classify each ... that is more effective. The discovery was a ... Molecular and Cell Biology (IMCB), and the Cancer ... National University of Singapore (NUS). , Despite advancements ...
(Date:8/20/2014)... Mass., (PRWEB) August 20, 2014 ... new report, PHOTONIC SENSORS AND DETECTORS: TECHNOLOGIES ... and detectors market is expected to grow to ... annual growth rate (CAGR) of 15.9%. Increasing ... region. , With a rapidly expanding range of ...
(Date:8/20/2014)... August 20, 2014 The finalists are ... leading health-marketing industry trade magazine, will honor the pharmaceutical ... Awards are given to outstanding companies, marketers and brand ... , “We are proud to announce that we ... entries with double the number of submissions we received ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 Little ... product—the Really Little Green Pouch —to meet growing ... feed babies and toddlers homemade foods. , “The ... Green Pouch co-founder Maggie Crawford. She continues, “Parents ... to limit exposure to things like pesticides and hidden ...
(Date:8/20/2014)... One Call Alert expands its line of ... a fully-mobile wearable device that connects customers to the help ... hours a day, 365 days a year. , ResCube can ... It operates on the T-Mobile nationwide network like a cell ... work. , Like with the other One Call Alert systems, ...
Breaking Medicine News(10 mins):Health News:Novel gene predicts both breast cancer relapse and response to chemotherapy 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 4Health News:PM360 Announces 2014 Trailblazer Award Finalists 5Health News:PM360 Announces 2014 Trailblazer Award Finalists 6Health News:PM360 Announces 2014 Trailblazer Award Finalists 7Health News:PM360 Announces 2014 Trailblazer Award Finalists 8Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 3
... Centers, Inc.,("GNC" the "Company" or "we"), the largest ... financial results for the third,quarter ended September 30, ... owned subsidiary of GNC Parent LLC,which was acquired ... Teachers, Pension Plan Board ("Teachers") through a merger ...
... RealAge features sneak peek and tips from YOU Docs, ... favorite doctors Mehmet,Oz, MD, and Michael Roizen, MD, first ... New York Times #1 best-seller in 2005. Now,these same ... YOU book series -- want to know, "What stands ...
... Holiday Gifts by November 20th to Support Free Delivery for ... Christmas, Express Option Also Available, ... ) a leading online retailer of health, beauty, vision, and,pharmacy ... troops at APO/FPO addresses around the world to take,advantage of ...
... Planning Guide for Los Angeles, SEATTLE, Nov. 11 ... guides to help them explore ideas and connect with,local ... a funeral,have none -- until now. The new LAFuneralGuide.com ... Angeles., "We want to help people consider all ...
... Winthrop-University Hospital celebrated its move to a new home. ... families gathered to form a "Life Line," or bridge, ... to the new Center at 120 Mineola Boulevard, suite ... was passed from person to person signifying the transfer ...
... Expanding for Plaintiffs with In Utero Injuries, is now available free from ... office is posting legal articles on their website in an effort to ... link to the full article. , ... Chicago, IL (PRWEB) November 11, ...
Cached Medicine News:Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 2Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 3Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 4Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 5Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 6Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 7Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 8Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 9Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 10Health News:Doctors Reveal Biology of Beauty in New Book 2Health News:drugstore.com Offers Free Shipping to U.S. Troops Serving Overseas and in the United States 2Health News:drugstore.com Offers Free Shipping to U.S. Troops Serving Overseas and in the United States 3Health News:Horse Drawn Hearse and Ash Scattering by Balloon - Hello LAFuneralGuide.com! 2Health News:Horse Drawn Hearse and Ash Scattering by Balloon - Hello LAFuneralGuide.com! 3Health News:Over 200 Patients and Families Create a Human Chain to Open A New Home for the Winthrop-University Hospital Cancer Center for Kids 2Health News:Free Article Now Available: 'Rights Expanding for Plaintiffs with In Utero Injuries' 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: